Rigor Reviewed

Rigor-Reviewed Manuscript

Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial.

Name: Αlpha¹ Rigor Record — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial.
Item: Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial.
Rating: 39
Author: Αlpha¹

Sanmarti R, Pérez-García C, de-Toro FJ, Salvador G, Escudero-Contreras A, Cuervo A, Graell E, Reina D, Kanterewicz E, Corominas H, Urionaguena-Onaindia I, López-Lasanta M, Olivé A, Sala-Gómez M, Frade-Sosa B, Morlà-Novell RM, Polino L, Meraz-Ostiz JA, Oreiro N, Blanco FJ, Pérez-Nadales I, Ortega-Castro R, Busquets-Pérez N, Gómez-Centeno AD, Camacho O, Rodríguez-Cros JR, Millan-Arciniegas AM, García-Llorente JF, Borrell H, Prior-Español Á, Castell-Quiñones S, Cruceta A, Bonfill E, Domenech-Gómez G, Roca-Fàbregas A, Ríos J, Tobalina-Maestre L, Gómara MJ, Haro I

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1★ (Critical), 2 critical, 2 high issues for “Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×3−3★
IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ReportingStudy design partially met−0.25★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed. These checks need the count the mean was averaged over, so none was performed.

Problems surfaced6 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

Critical findings

• PERCENT: 22.9% does not match the reported count 8/36
• PERCENT: 22.9% does not match the reported count 8/36
• PERCENT: 1.8% does not match the reported count 4/34

The paper is a well-conducted randomized open-label trial with a clear scientific premise, rigorous randomization, and adequate reporting of ethics, biological variables, and key resources. The main weaknesses are the open-label design, vague data availability, and minor statistical reporting gaps.

Both reviewers classified the study as interventional; no divergence. The evaluation covered all eight dimensions; several sub-criteria were not applicable for a human clinical trial (e.g., housing conditions, cell line authentication). The statistics verification component checked only a subset of tests; the 3 inconsistent recomputations were not flagged as decision errors and may reflect rounding.

7 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 2 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks. 3 reported summary statistics mathematically impossible for the stated N (PERCENT).

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

Prior work is cited extensively, including observational studies on PR progression to RA, placebo-controlled trials of abatacept and rituximab in at-risk populations, and the rationale for using hydroxychloroquine as a comparator. The premise that PR is a preclinical RA state and that T cell activation is a key target is logically linked to the study objectives. Limitations of prior research (e.g., lack of RCTs in PR, small sample sizes, short follow-up) are acknowledged and addressed by the study design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise by citing prior work on palindromic rheumatism as a precursor to RA, the role of autoantibodies, and previous prevention trials with biologic DMARDs.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“A high proportion of individuals with PR develop RA (30–60% in most series)... Three placebo-controlled trials have shown the efficacy of biologic disease-modifying anti-rheumatic drugs (DMARDs) in delaying the onset of RA with the anti-B cell rituximab or preventing its onset with the T cell down-modulator abatacept.”

paraphrase[Introduction, paragraph 4]

“The key role of T cell activation in the preclinical and early phases of RA and the efficacy and safety of its inhibition with abatacept... position abatacept as a suitable alternative for a prevention trial in individuals with PR at risk of RA.”

direct quote[Discussion, paragraph 1]

“As we know of no other randomized clinical trials in patients with PR, we cannot compare our results with those of other trials of individuals with PR.”